Similar articles

• Epothilones and the next generation of phase III trials for prostate cancer.

  Bhandari MS, Hussain M. Bhandari MS, et al. BJU Int. 2005 Aug;96(3):296-302. doi: 10.1111/j.1464-410X.2005.05618.x. BJU Int. 2005. PMID: 16042717 Review. No abstract available.
• An interdisciplinary approach to treating prostate cancer.

  Kibel AS. Kibel AS. Urology. 2005 Jun;65(6 Suppl):13-8. doi: 10.1016/j.urology.2005.03.079. Urology. 2005. PMID: 15939078 Review.
• The current role of chemotherapy in metastatic hormone-refractory prostate cancer.

  Petrylak DP. Petrylak DP. Urology. 2005 May;65(5 Suppl):3-7; discussion 7-8. doi: 10.1016/j.urology.2005.03.053. Urology. 2005. PMID: 15885271 Review.
• Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

  Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G. Scher HI, et al. J Clin Oncol. 2011 Jun 1;29(16):2191-8. doi: 10.1200/JCO.2010.32.8815. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483004 Clinical Trial.
• [Hormone-refractory metastatic prostate carcinoma -- combination improves survival].

  [No authors listed] [No authors listed] Aktuelle Urol. 2005 Sep;36(5):385-7. doi: 10.1055/s-2005-915498-3. Aktuelle Urol. 2005. PMID: 16163602 German. No abstract available.